Lockyer M. Walking can reduce CVD risk in impaired glucose tolerance. Practitioner 2014; 258 (1770): 8

Walking can reduce CVD risk in impaired glucose tolerance

22 Apr 2014Pais-up subscribers

Increasing ambulatory activity reduces cardiovascular events in patients with impaired glucose tolerance and raised risk, data from the Navigator trial has shown. The main objective of the original study was to determine whether valsartan or nateglinide prevented cardiovascular events and/or progression of impaired glucose tolerance to overt diabetes. The findings did not show any protective effect from either drug. However, as well as the original research question posed by the trial, the cohort provided a large amount of prospective data for further analysis.  The current paper analysed the relationship between change in daily ambulatory activity and cardiovascular events.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article